Zobrazeno 1 - 10
of 398
pro vyhledávání: ''
Autor:
Maya Koren-Michowitz, Sharon Gino-Moor, Miri Zektser, Jacob M. Rowe, Galit Peretz, Shay Yeganeh, Chezi Ganzel, Ronit Yerushalmi, Alexander Gural, Vladimir Vainstein, Ivetta Danylesko, Boaz Nachmias, Yosef Cohen, Arie Apel, Yishai Ofran, Yakir Moshe, Ron Ram, Oren Pasvolsky, Ofir Wolach
Publikováno v:
Leukemialymphoma. 61(9)
Data from 11 Israeli centers, where venetoclax was used for relapsed/refractory AML after intensive chemotherapy, were retrospectively collected. During 2016-2019, forty patients were identified. Median age was 67 years (21-82), 60% males, median of
Autor:
Kenneth J. C. Lim, Gavin Cull, Kate Denning, Michael F. Leahy, David Joske, Andrew P. Hutchison, Matthew Wright, James Anton Kuzich, Portia Smallbone, Dejan Radeski, Duncan Purtill
Publikováno v:
Leukemialymphoma. 60(14)
We present an analysis of 98 consecutive patients with peripheral T-cell lymphoma (PTCL) treated over a 10-year period within Western Australia. The most common frontline therapies were CHO(E)P (47%), HyperCVAD (21%), and reduced intensity therapy or
Autor:
Xinyi Lin, Fei Qi, Shunan Qi, Shulian Wang, Yongwen Song, Shengyu Zhou, Jianliang Yang, Hui Fang, Yexiong Li, Mei Dong, Bo Chen, Sheng Yang, Lin Gui, Jingjing Wang, Peng Liu
Publikováno v:
Leukemialymphoma. 60(11)
Early/upfront radiation was associated with improved survivals compared with late radiation for early-stage NK/T-cell lymphoma (NKTCL) in the old era when anthracycline-base chemotherapy (CT) prevailed. However, in the modern era of effective l-aspar
Publikováno v:
Leuk Lymphoma
Using data from the National Cancer Data Base, 2010–2015, we examined characteristics and outcomes of T-cell/histiocyte-rich large B-cell lymphoma (THRLBCL, N=622) relative to unspecified diffuse large B-cell lymphoma (DLBCL-NOS, N=91,588) and nodu
Autor:
Francesco Merli, Luca Nassi, Monica Tani, Flavia Salvi, Vincenzo Pavone, Marco Ladetto, Manuela Zanni, Annalisa Peli, Stefano Volpetti, Riccardo Centurioni, Stefano Luminari, Annalisa Arcari, Alessandro Re, Michele Spina, Alessandro Pulsoni, Andrea Evangelista, Anna Marina Liberati, Alessandra Tucci, Roberto Freilone, Gerardo Musuraca, Caterina Patti, Caterina Stelitano, Stefania Massidda
Publikováno v:
Leukemialymphoma. 60(12)
This phase-II study assessed activity and toxicity of substituting conventional doxorubicin with nonpegylated liposomal doxorubicin in the conventional ABVD regimen for the treatment of elderly or cardiopathic patients with HL. Stage I-IIA and IIB-IV
Autor:
Kaplanov, K. D., ÖZCAN, MEHMET ALİ, Udovitsa, D. P., Ilyin, N., Alekseev, S. M., Fadjari, H., Arumugan, V., Chakrabarti, P., Kirushnakumar, K. S., Attili, A. V. S. Suresh, Dantas da Cunha Junior, A., Schmidt Filho, J., Franke, F. A., Sampaio Tavares, R., Pinto Simoes, B., Miguel, C. E., Meton, F., Boquimpani, C., Schaffel, R., Cigno, E. L., Basso, A. C., Jarchum, G., Heller, V. B., Bullorsky, E., Furque, M. L., Jones, L., Bassa, F., Osmanov, D. S., Burdaeva, O. N., Melnichenko, V. Y., Uy, N. A., Keat, C. Teng, Rosales, J. D., Galvez, K., Lazaretti, N., Debiasi, M., Santi, P. Xavier, de Mattos, E. R., Luiz da Silva, R., Rodrigues de Oliveira, J. S., Pereira, J., Salvino de Araujo, A., Fogliatto, L., Beguelin, G. Z., Saslavsky, M. M., Munoz, M., Avila, G. I., Moiseevich, M. G., Viktorovich, P. A., Tiangco, B. J., Molina Barrios, G. R., Martinez-Lapus, F. G. P., Villegas, E. M., Raman, R., Gin, G. Gin, Bermudez, C., Ciliao Munhoz, E., Garcia, J. J., De Stefano, G., Caffaro, J., Syafei, S., da Silva Araujo, S. Shusterschitz, Kowalyszyn, R. D., Jasuja, S., Bhurani, D., Radhakrishnan, V., Salvatierra, A., Mukhopadhyay, A., Bhattacharyya, S., Bhatt, N., Perez Diaz, Luis, Paravisini, Alexandra, Fogliatto, Laura, Nodehi, Sayyed Reza Safaee, Patel, Moosa, Volodicheva, Elena Mikhailovna, Lipatov, Oleg Nikolaevich, Guan, Toh See, Querol, John, Flores, David Hugo, Dasappa, Lokanatha, Beniwal, Surender Kumar, Bar, Daniel Oscar, Delamain, Marcia Torresan, Gonzalez, Derlis E., Candelaria, Myrna, Florez, A., Michiels, S., Leao, D., Loggetto, S. R., Szpak, W., Lifirenko, I. D., Ponomarev, R. S., Lysenko, I. B., Vladimirov, V.
Publikováno v:
Leukemialymphoma. 60(14)
This multicenter, double-blind, randomized study compared the efficacy, pharmacokinetics (PKs)/pharmacodynamics (PDs), safety and immunogenicity profile of RTXM83 vs. reference rituximab (R-rituximab), both with CHOP, as first-line treatment of diffu
Autor:
Nathan Fowler, Sweet Ping Ng, Bouthaina S. Dabaja, Jillian R. Gunther, Sarah A. Milgrom, Zeina Ayoub, T.Y. Andraos, Chelsea C. Pinnix, Felipe Samaniego, Luis Fayad, Sattva S. Neelapu, Loretta J. Nastoupil
Publikováno v:
Leukemialymphoma. 60(13)
Patients with early-stage nodal follicular lymphoma (FL) may be rendered free of detectable disease by a diagnostic excisional biopsy. We reviewed the management and outcomes of 48 patients with FL, diagnosed from 2003-2013, treated at a single insti
Autor:
Thomas M. Habermann, Erin F. Barreto, Ross A. Dierkhising, Heather A. Personett, Kristen B. McCullough, Nelson Leung
Publikováno v:
Leukemialymphoma. 60(9)
Early administration of rasburicase to enhance uric acid (UA) elimination has been adopted without robust evidence in support of its impact on clinical outcomes in tumor lysis syndrome (TLS), specifically, the prevention of acute kidney injury (AKI).
Autor:
Young Rok Do, Jung Yong Hong, Won Sik Lee, Byeong Bae Park, Young Il Koh, Min Kyoung Kim, Seung Sook Lee, Jeong-A Kim, Shin Young Hyun, Deok Hwan Yang, Cheolwon Suh, Jong Ho Won, Won Seog Kim, Young Ha Oh, Jae Cheol Jo
Publikováno v:
Leukemialymphoma. 60(13)
This trial was designed to investigate the efficacy and toxicity of bendamustine, carboplatin, and dexamethasone (BCD) for relapsed or refractory peripheral T-cell lymphomas (PTCLs), which would be expected to exhibit more promising clinical outcomes
Autor:
Ernesta Audisio, Mario Boccadoro, Marco Cerrano, Stefano D'Ardia, Elena Crisà, Benedetto Bruno, Dario Ferrero, Anna Candoni, Maria Elena Zannier, Maria Vittoria Dubbini
Publikováno v:
Leukemialymphoma. 60(13)
Prognosis of elderly acute myeloid leukemia (AML) patients remains dismal with less than 15–20% of long-term survivors. Though challenged by hypomethylating agents (HMA), intensive chemotherapy (IC...